James C. Yang

Cancer immunotherapy: moving beyond current vaccines

Steven A. Rosenberg, James C. Yang, Nicholas P. Restifo · Nature Medicine · 2004 · 3K citations · Full text

Medicine, Immunology, Oncology +14

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Richard A. Morgan, James C. Yang, Mio Kitano et al. · Molecular Therapy · 2010 · 2.5K citations · Full text

Life Sciences, Immunology, Oncology +17

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

Eric Tran, Simon Turcotte, Alena Gros et al. · Science · 2014 · 1.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Paul F. Robbins, Richard A. Morgan, Steven A. Feldman et al. · Journal of Clinical Oncology · 2011 · 1.6K citations · Full text

Life Sciences, Immunology, Oncology +17

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

Medicine, Hematology, Oncology +17